Gilead Sciences, Inc. made a substantial bet on moving into a different kind of liver disease with its $4.3bn takeout in February of CymaBay Therapeutics, Inc., and that transaction is beginning to bear fruit with the US Food and Drug Administration approval on 14 August of Livdelzi (seladelpar) for second-line treatment of primary biliary cholangitis (PBC). In that setting, Livdelzi will compete against two second-line agents, Alfasigma S.p.A.’s Ocaliva (obeticholic acid), approved in 2016, and Ipsen SA/Genfit SA’s Iqirvo (elafibranor), which obtained FDA approval in June.
Gilead Becomes Third To Market In Second-Line PBC, With Label Advantages
Gilead will make the case that Livdelzi is a better treatment option than Ocaliva or recently approved Iqirvo due to its ability to alleviate pruritus and reduce ALP levels.
More from New Products
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
More from Scrip
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.